Publications & Posters

WCLC 2024: A Phase Ib Study to Evaluate HMBD‑001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD‑001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers

AACR 2024: The VISTA blocking antibody HMBD-002 promotes type-I interferon signaling and drives anti-tumor responses through macrophage reprograming and cytotoxic CD8+ T cell activation

AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

ESMO 2023: A CRUK phase I/IIA, first in human dose‐escalation and expansion trial of HMBD‐001 (an anti‐HER3 antibody) in patients with advanced HER3 positive solid tumours

HMBD-001 is Hummingbird Bioscience’s proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and…

WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

AACR 2023: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker selected pre-clinical models of squamous cell carcinomas